Growth At Corange In 1995

30 June 1996

Corange of Bermuda, parent company of the German firm Boehringer Mannheim, achieved net income in 1995 of $316.4 million, up 46.7%. Operational income was ahead 16.8% to $485 million. Sales for the year were $3.9 billion, up 14%.

The Boehringer Mannheim group produced 83% of Corange's 1995 revenues with $3.3 billion. The German firm's therapeutics division achieved turnover of $1.1 billion, the patient care division generated sales of $978 million, laboratory diagnostics sales were $1 billion, and the biochemicals division achieved turnover of $222 million. All divisions posted growth in 1995.

The DuPuy group, an orthopedics business, reported sales of $657 million, up 14%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight